Publications by authors named "David M Njoo"
J Dermatolog Treat
August 2022
Article Synopsis
- Biologics for psoriasis can be safely reduced in dosage for patients with low disease activity to avoid overtreatment and reduce costs, though concerns about increased anti-drug antibody (ADA) formation exist.
- * The study involved 118 patients who were randomly assigned to either dose reduction (DR) or usual care (UC) over one year, examining serum drug concentrations and ADA levels.
- *Results showed no significant difference in ADA levels for adalimumab between DR and UC, and no relevant ADA development for ustekinumab; this suggests that dose tapering may not increase immunogenicity in low disease activity psoriasis patients.
